Translational Research Center for Gastrointestinal Diseases (TARGID), University of Leuven, Leuven, Belgium.
Am J Gastroenterol. 2019 Feb;114(2):204-206. doi: 10.14309/ajg.0000000000000072.
Functional dyspepsia (FD) is subdivided into epigastric pain syndrome and postprandial distress syndrome according to the Rome IV consensus. Based on the assumption that disordered gastric motility is a key pathophysiologic factor in postprandial distress syndrome, prokinetic agents are often proposed as the treatment of choice for this subgroup. Although a meta-analysis suggests that prokinetic agents may be efficacious and safe in FD, there is a lack of widely available agents of proven efficacy. This review analyzes some of the difficulties and challenges in establishing therapeutic efficacy of prokinetic drugs in FD.
功能性消化不良（FD）根据罗马 IV 共识分为上腹痛综合征和餐后不适综合征。基于餐后不适综合征的关键病理生理因素是胃动力紊乱的假设，常提议使用促动力药物作为该亚组的治疗选择。虽然荟萃分析表明促动力药物在 FD 中可能有效且安全，但缺乏广泛可用且疗效已证实的药物。本文分析了在 FD 中确立促动力药物治疗疗效方面存在的一些困难和挑战。
